What Chongqing Chenan Biopharmaceutical Co., Ltd. does

Chongqing Chenan Biopharmaceutical Co., Ltd. is a privately held Chinese biopharmaceutical company founded in late 2015 and headquartered in Chongqing International Bio-city, Banan District. The company specializes in the R&D and manufacturing of recombinant protein therapeutics for chronic metabolic diseases, primarily diabetes and obesity, with a technology platform spanning the full insulin analog spectrum (ultra-rapid-acting, rapid-acting, intermediate-acting, long-acting, ultra-long-acting, and pre-mixed varieties), GLP-1 receptor agonists (including weekly and oral formulations), and a next-generation dual GIP/GLP-1 receptor agonist pipeline protected by six granted Chinese invention patents. It operates an integrated R&D-to-commercial infrastructure comprising a 7,500 sqm GMP-compliant pilot R&D center and a 55,000 sqm industrial production base with two 10-ton fermentation-scale drug substance workshops and automated cartridge PFS filling lines, targeting 50 million insulin analog units of annual capacity. The company employs approximately 200 staff, with 46% of headcount in R&D roles holding bachelor's degrees or above.

Chenan is currently pre-commercial. Its lead assets — liraglutide injection and insulin degludec injection — are under NMPA marketing review, while semaglutide injection and a degludec/aspart compound formulation have completed clinical trials, and CA502 (rapid-acting insulin), CA505 (weekly GLP-1), CA508 (degludec/aspart compound), and CA111 are in various clinical phases. The company has secured seven clinical trial approvals, a Manufacturing License of Pharmaceuticals from the Chongqing Medical Products Administration (June 2022), and National High-tech Enterprise recognition (November 2024).

The company's business model is a B2B hospital and clinic distribution channel targeting Chinese healthcare institutions, to be executed through the established commercial network of its strategic investor and parent affiliate Chongqing Zhifei Biological Products Co., Ltd. (300122.SZ). Revenue is currently non-existent at commercial scale; future revenue will depend on NMPA approval and commercial launch of the pipeline products, with a long-term combined industrial output target exceeding RMB 20 billion across all three construction phases. The R&D roadmap is extending into obesity and metabolic dysfunction-associated steatohepatitis (MASH) via the newly opened Shanghai Innovation Incubator Center in Pudong New Area.

Name

Chongqing Chenan Biopharmaceutical Co., Ltd.

Legal name

Chongqing Chenan Biopharmaceutical Co., Ltd.

Website

https://chenanbio.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Chongqing Chenan Biopharmaceutical is a Chinese biopharmaceutical company developing and manufacturing recombinant protein therapeutics for diabetes, obesity, and metabolic diseases, currently advancing insulin analogs, GLP-1 receptor agonists, and dual GIP/GLP-1 agonists through clinical and regulatory stages.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals — Diabetes and Metabolic Disease Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity) (HLAIAAAE)

akta.pro secondary industry

Pen Injectors (Insulin/GLP-1/Other Pens) (HLAHAIAC)

Keywords

• Recombinant protein therapeutics
• Insulin analogs
• GLP-1 receptor agonists
• Diabetes therapeutics
• Biopharmaceutical manufacturing

Headquarters

HQ city

Chongqing Shi

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Revenue generated from sales of diabetes therapeutic drugs including insulin analogs and GLP-1 receptor agonists. Products are currently in clinical trial stages with liraglutide injection and insulin degludec injection under marketing review.
2. Future Product Pipeline: Semaglutide injection, insulin degludec/aspart compound formulation, and other metabolic disease treatments expected to contribute to revenue as products receive regulatory approval and launch commercially.

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Chongqing Chenan Biopharmaceutical Co., Ltd. is a high-tech biopharmaceutical company that researches, develops, and manufactures therapeutic recombinant protein drugs for chronic metabolic diseases, primarily diabetes and obesity. Its portfolio covers insulin analogs (rapid-acting, intermediate-acting, long-acting, ultra-long-acting, and pre-mixed) and GLP-1 receptor agonists (liraglutide, semaglutide, and weekly ultra-long-acting formulations), supported by proprietary dual GIP/GLP-1 receptor agonist technology and pen-injector delivery systems.

Product overview

Chongqing Chenan Biopharmaceutical Co., Ltd. is a biopharmaceutical company specializing in therapeutic drugs for chronic metabolic diseases including diabetes and obesity. The company operates an integrated platform combining pilot-scale R&D with large-scale industrialization capabilities. The core product portfolio includes: (1) Insulin analogs spanning ultra-rapid-acting, rapid-acting, intermediate-acting, long-acting, ultra-long-acting, and pre-mixed formulations; (2) GLP-1 receptor agonists including liraglutide, semaglutide (injectable and oral), and weekly formulations like CA505; (3) Combination products such as CA508 degludec/aspart compound formulation and degludec/insulin aspart dual insulin; (4) Delivery devices including pen-injectors; and (5) Pharmaceutical intermediates like modifiers and tool enzymes. Key products in late-stage development include liraglutide injection and degludec insulin injection (both in marketing review), semaglutide injection and degludec/aspart dual insulin injection (clinical trials completed), with CA502, CA505, CA508, and CA111 in various clinical phases. The company is expanding into weight management and metabolic dysfunction-associated steatohepatitis (MASH) through its new Shanghai Innovation Incubator Center.

Differentiator

Problem solved

Functional benefit

Products and services

• Liraglutide Injection (利拉鲁肽注射液)
• Degludec Insulin Injection (德谷胰岛素注射液)
• Semaglutide Injection (司美格鲁肽注射液)
• Degludec/Aspart Dual Insulin Injection (德谷门冬双胰岛素注射液)
• Oral Semaglutide Preparations (口服司美格鲁肽制剂)
• Insulin Analogs Portfolio (胰岛素类似物)
• GLP-1 Analogs Portfolio (GLP-1类似物)
• Pen-Injector Delivery Device (笔式注射器)

Quantifiable outcome

• Expected annual production capacity of 50 million insulin analog finished products
• +2 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Two partnerships are on record, tiered minor.

• Chongqing University of Technology - School of Pharmacy and Bioengineering (重庆理工大学药学与生物工程学院)minorStrategic or Co-development Partner · 15 September 2021Project cooperation agreement for development of oral Semaglutide preparations signed September 15, 2021. This is Chenan's first project collaboration with a university, marking a significant step in school-enterprise cooperation. The partnership aims to leverage academic research capabilities for pharmaceutical product development, particularly in oral formulations of GLP-1 analogs.
• Chongqing University of Technology - School of Pharmacy and Bioengineering (重庆理工大学药学与生物工程学院)minorStrategic or Co-development Partner · 28 April 2021University-enterprise产学研 cooperation agreement signed April 28, 2021. The partnership includes talent cultivation, high-tech talent exchange, resource sharing, and project cooperation. The school established an 'Employment Internship Training Base' at Chenan, while Chenan established a 'Human Resources Training Base' at the university. This collaboration supports Chenan's talent recruitment and R&D capabilities.

Scale indicators13 records

Recent moves10 records

Expansion highlights7 records

Emerging players

• Sciwind Biosciences: Chinese clinical-stage biopharma (派格生物医药) developing long-acting GLP-1 receptor agonists and metabolic disease therapeutics — comparable as a domestic Chinese GLP-1-focused emerging player targeting the same diabetes/obesity markets as Chenan.
• Wenzhou Biocaro Pharma / Hua Medicine: Chinese biotech developing innovative metabolic-disease therapies focused on diabetes and related indications — partially comparable as a domestic Chinese metabolic-disease-focused emerging player addressing the same therapeutic area as Chenan.
• PegBio: Chinese clinical-stage biopharma developing long-acting GLP-1 receptor agonists and metabolic peptides (PegBio Co., Ltd.) — comparable as a domestic Chinese GLP-1 emerging player targeting obesity and diabetes indications that overlap with Chenan's pipeline focus.

Broad incumbents

• Jiangsu Hengrui Pharmaceuticals: Largest Chinese pharmaceutical company with broad therapeutic coverage including diabetes and metabolic products plus extensive hospital sales infrastructure — broadly comparable as a dominant Chinese branded pharma with nationwide hospital access that Chenan competes against for formulary positioning.
• Novo Nordisk: Global leader in diabetes care and originator of liraglutide, semaglutide (Ozempic/Wegovy), insulin degludec (Tresiba), and dual GIP/GLP-1 development — directly comparable molecule-for-molecule with Chenan's pipeline, and the dominant incumbent Chenan must differentiate against.
• Innovent Biologics: Major Chinese biopharmaceutical company (信达生物) with a portfolio spanning oncology and metabolic diseases, including GLP-1/incretin programs — broadly comparable as a large-cap Chinese listed biopharma operating at the intersection of biologics manufacturing and metabolic therapeutics.
• Eli Lilly: Global innovator of tirzepatide (Mounjaro/Zepbound), the dual GIP/GLP-1 receptor agonist that validates Chenan's proprietary dual-agonist approach — broadly comparable as a metabolic-disease incumbent operating across insulin and incretin franchises Chenan is targeting.

Direct peers

• Tonghua Dongbao Pharmaceutical: Major Chinese insulin manufacturer (通化东宝) producing recombinant human insulin and insulin analogs for diabetes treatment in China — directly comparable as a domestic recombinant insulin competitor serving the same hospital procurement channels as Chenan.
• Gan & Lee Pharmaceuticals: Chinese insulin analog specialist (甘李药业) developing and commercializing recombinant insulin analogs including long-acting and rapid-acting formulations — directly comparable as a domestic Chinese insulin biologic manufacturer with overlapping mechanism and target market as Chenan.

Others

• Betta Pharmaceuticals: Chinese biopharmaceutical company (贝达药业) with innovation-focused R&D in oncology and other specialty therapeutics — adjacent peer as a domestic Chinese listed biopharma with biologics development capabilities, though operating in different therapeutic specialties than Chenan.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chongqing Chenan Biopharmaceutical Co., Ltd.